Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?

Reported by Yahoo Finance · Published 25 Aug 2026, 10:21 PM MYT (1 hr ago)

Image: Yahoo Finance

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?

Summary

More in Markets

Dick’s Sporting Goods’ stock is having its worst day ever, as sneakers aren’t selling without deeper discounts

Amcor supplies Tiptree with certified 30% PCR films

Berkshire Hathaway Bought $10 Billion of Alphabet Straight From the Company, Bypassing the Open Market

My old job had a pension and they offered me to cash out for $24k or get $100 per month for life — which should I choose?

Ray Dalio says the US faces a debt crisis ‘in three years, give or take two.’ 5 things Americans can do now

Affirm (AFRM) Slipped After Klarna Cut Guidance. Category Warning or Share-Gain Opportunity?